Protic, Marijana; Seibold, Frank Werner; Schöpfer, Alain; Radojicic, Zoran; Juillerat, Pascal; Bojic, Daniela; Mwinyi, Jessica; Mottet, Christian; Jojic, Njegica; Beglinger, Christoph; Vavricka, Stephan; Rogler, Gerhard; Frei, Pascal (2014). The effectiveness and safety of rescue treatments in 108 patients with steroid-refractory ulcerative colitis with sequential rescue therapies in a subgroup of patients. Journal of Crohn's & Colitis, 8(11), pp. 1427-1437. Elsevier 10.1016/j.crohns.2014.05.004
Text
The effectiveness and safety of rescue.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (1MB) |
BACKGROUND:
Among patients with steroid-refractory ulcerative colitis (UC) in whom a first rescue therapy has failed, a second line salvage treatment can be considered to avoid colectomy.
AIM:
To evaluate the efficacy and safety of second or third line rescue therapy over a one-year period.
METHODS:
Response to single or sequential rescue treatments with infliximab (5mg/kg intravenously (iv) at week 0, 2, 6 and then every 8weeks), ciclosporin (iv 2mg/kg/daily and then oral 5mg/kg/daily) or tacrolimus (0.05mg/kg divided in 2 doses) in steroid-refractory moderate to severe UC patients from 7 Swiss and 1 Serbian tertiary IBD centers was retrospectively studied. The primary endpoint was the one year colectomy rate.
RESULTS:
60% of patients responded to the first rescue therapy, 10% went to colectomy and 30% non-responders were switched to a 2(nd) line rescue treatment. 66% of patients responded to the 2(nd) line treatment whereas 34% failed, of which 15% went to colectomy and 19% received a 3(rd) line rescue treatment. Among those, 50% patients went to colectomy. Overall colectomy rate of the whole cohort was 18%. Steroid-free remission rate was 39%. The adverse event rates were 33%, 37.5% and 30% for the first, second and third line treatment respectively.
CONCLUSION:
Our data show that medical intervention even with 2(nd) and 3(rd) rescue treatments decreased colectomy frequency within one year of follow up. A longer follow-up will be necessary to investigate whether sequential therapy will only postpone colectomy and what percentage of patients will remain in long-term remission.
Item Type: |
Journal Article (Original Article) |
---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Gastroenterology |
UniBE Contributor: |
Seibold, Frank Werner, Schöpfer, Alain, Juillerat, Pascal |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1873-9946 |
Publisher: |
Elsevier |
Language: |
English |
Submitter: |
Lilian Karin Smith-Wirth |
Date Deposited: |
22 Apr 2015 08:55 |
Last Modified: |
05 Dec 2022 14:45 |
Publisher DOI: |
10.1016/j.crohns.2014.05.004 |
PubMed ID: |
24908178 |
Uncontrolled Keywords: |
Ciclosporin; Inflammatory bowel disease; Infliximab; Tacrolimus; Ulcerative colitis |
BORIS DOI: |
10.7892/boris.66970 |
URI: |
https://boris.unibe.ch/id/eprint/66970 |